$RGEN · REPLIGEN CORP
Repligen reported Q3 2026 revenue of $209.3M, up 11% reported and 12.5% organic year-over-year. GAAP results swung to a loss of $(0.68) per diluted share, driven by a $41.2M intangible asset impairment charge. Adjusted (non-GAAP) diluted EPS was $0.53, up from $0.46 a year ago, with adjusted operating margin expanding to 15.9%. The company raised full-year 2026 revenue guidance to $844M–$852M, reflecting 14.5%–15.5% reported growth and incorporating the October 6 BioLife Solutions acquisition.
- Q3 revenue $209.3M, +11% reported / +12.5% organic YoY, driven by consumables and capital equipment order book growth.
- GAAP operating loss of $29.5M includes a $41.2M intangible asset impairment charge; GAAP diluted EPS was $(0.68).
- Adjusted (non-GAAP) diluted EPS of $0.53 vs. $0.46 a year ago; adjusted operating margin expanded to 15.9% from 14.2%.
- FY26 revenue guidance raised to $844M–$852M (14.5%–15.5% reported growth), including ~2.5 pts from BioLife acquisition net of Polymem divestiture.
- Cash and marketable securities stood at $863M at quarter-end, up from $768M at December 31, 2025.
Markets closed — no regular-session reaction yet. Extended-hours last trade at $180.00, down 0.09% from the regular close, suggesting a muted initial response to the mixed quarter (GAAP loss on impairment vs. raised guidance).
A $41.2M impairment charge cratered GAAP earnings even as organic growth accelerated to 12.5% and full-year guidance was raised — a classic "noisy quarter" that tests whether investors focus on the underlying business momentum or the writedown.
Repligen's 12.5% organic growth and raised guidance signal improving end-market demand in bioprocessing consumables and capital equipment, a positive read-through for the broader bioprocessing tools and CDMO supply chain.
$41.2M intangible asset impairment charge drove the GAAP operating loss; BioLife integration risk is explicitly flagged, including potential disruptions to customer, supplier, and employee relationships. Tariff exposure and internal-control effectiveness are also cited.